Loading
A phase 2 trial of Imetelstat in myelodysplastic syndromes / neoplasms and acute myeloid leukaemia, run by GCP-Service International West GmbH, active and no longer recruiting.
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy is a phase 2 interventional study registered as NCT05583552 by GCP-Service International West GmbH, with 46 participants enrolled, started 2023-06-05 and due to reach its primary completion in 2025-03-27. Interventions recorded: Imetelstat sodium. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
46 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2026-05-12), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall Hematological Response Rate of Participants After Treatment With Imetelstatprimary | Imetelstat Sodium (1 Treatment / Cycle) | 23 | 0 participants | - | - | link |
| Imetelstat Sodium (2 Treatments / Cycle) | 23 | 1 participants |
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.